Along this line, our observations in patients indicate that HER2+ breast tumors with increased expression of NK-IL2RS, NK and NKT cell signatures previous to treatment will respond better to anti-HER2 mAbs-based therapy. Here, ERBB2 is linked to breast neoplasm.